Gotta say it - although it's not 'new' news, the 19.6 month median survival rate for castrate-resistant prostate cancer is an outstanding result. Let's not lose sight of that, and the fact this was achieved despite some of the patients being on sub-optimal doses. The final two hurdles as I see it are to demonstrate unequivocally the added value Idroxonil provides to LU-PSMA, and to secure IP (I take comfort in the recent change of stance from the US Patent Office, resulting in a reset of the claim process).
All in all, happy to be invested in this, and well done Dr Kelly for creating multiple opportunities to demonstrate the drug's worth. What a shame he wasn't given the chance to do the same with Cantrixil, the next-generation drug to Idronoxil - a completely squandered opportunity by those who forced Dr Kelly out of his own company, and then slumbered like dogs in a manger, showing no initiative whatsoever to promote the drug, and finally selling it for a song.
